In the late 1960s, scientists discovered a miracle drug for Parkinson’s disease – a simple, inexpensive dopamine-replacement pill called levodopa. It transformed the lives of millions of people. People who could barely rise from a chair could stand,walk,adn work again.
The late Robin Williams famously brought the drug’s promise into public view in the 1990 movie “Awakenings.” For more than half a century, levodopa has been the gold standard for treating Parkinson’s disease, and the treatment is taught to medical students worldwide. Yet in 2025, most of the world’s 11.8 million people with Parkinson’s cannot reliably get it.
Let that sink in. A generic, off-patent medication that costs pennies a dose – one that can restore dignity, mobility, and independence – is out of reach for many people who need it.This is not because we lack the science. Its as we lack the will, the systems, and the plan.
We’ve solved harder problems. Two decades ago, the HIV/AIDS epidemic was devastating the developing world. Lifesaving antiretroviral drugs existed but were locked behind high prices and weak global distribution. Through international coordination, policy changes, and sustained advocacy, we made those drugs available worldwide. Today, more than 29 million people are receiving treatment for HIV, turning what was once a death sentence into a livable and manageable condition. The hope is that the already implemented global systems and policies will sustain this success even with a decrease in funding from the United States.
So why can’t we do the same for Parkinson’s disease?
The barriers are depressingly familiar. In many low- and middle-income countries,levodopa is not on the shelves,or when it is,the supply is unreliable.Patients travel hours to reach a pharmacy, onyl to be told it’s out of stock. Counterfeit or substandard pills flood unregulated markets,leaving desperate families with medicines that don’t work. And when the drug is available,the cost can be crushing,forcing patients to choose between food and movement.
This isn’t just a supply chain problem. it’s a political and a moral failure.
Parkinson’s is the fastest-growing neurodegenerative disease in the world. its prevalence
Parkinson’s Disease: A Call for Global Access to Levodopa
The success of the global HIV response demonstrates the power of aligning science, policy, and activism to improve public health. For decades, systems have been in place to deliver daily medication to tens of millions across the globe. Given this achievement with complex HIV drug cocktails, the question arises: why isn’t a safe, shelf-stable, and well-tolerated oral tablet like levodopa readily accessible to those who need it for Parkinson’s disease?
Levodopa remains the gold standard treatment for managing the motor symptoms of Parkinson’s disease, a progressive neurological disorder affecting over 10 million people worldwide. https://www.parkinson.org/understanding-parkinsons/statistics/ Though, access to this essential medication remains a significant challenge for many, leading to unneeded disability and diminished quality of life.
The cost of providing levodopa is minimal compared to the profound benefits it offers.Effective treatment allows individuals to maintain mobility, continue working, and care for their families, avoiding the debilitating effects of untreated disease. Economically, this translates to reduced disability costs, lessened caregiver burden, and increased productivity. More importantly, it restores dignity and improves the lives of those living with Parkinson’s. https://pubmed.ncbi.nlm.nih.gov/37446441/
Currently, millions are unnecessarily experiencing the progression of disability due to lack of access. The situation echoes the early days of the HIV epidemic, when effective treatments existed but were not universally available. Denying access to levodopa sends a similar message to those with Parkinson’s – that their well-being is not a societal priority.
Addressing this issue requires a concerted effort. Levodopa access must be recognized as a basic human right and integrated into the global health agenda. Proactive measures are crucial,particularly as the number of Parkinson’s cases is projected to rise considerably,perhaps overwhelming healthcare systems. https://www.michaeljfox.org/parkinsons-disease/statistics/
The world demonstrated its capacity for collective action in combating HIV. we must replicate that success for Parkinson’s disease. A medication costing pennies should not be considered a luxury, and a life that can be restored should not be allowed to deteriorate.
Michael S. Okun and Ray Dorsey are authors of the new book, “the parkinson’s Plan.” Dorsey has worked as a consultant to companies that market levodopa formulations, but not on projects related to the drug.